Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 18, 2026

2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of

View original at finance.yahoo.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of Urban air mobility has long lived somewhere between science fiction and city planning decks…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For Joby fiscal 2026, loss projected to narrow 11.8% to -$0.75 per share

    80% confidence

  • Archer Aviation has consensus Moderate Buy rating overall

    80% confidence

  • For Archer fiscal 2026, losses expected to reduce 7.8% annually to -$0.95 per share

    80% confidence

  • For Archer current year, losses projected to decline 27.5% YOY to -$1.03 per share

    80% confidence

  • Urban air mobility has long lived somewhere between science fiction and city planning decks

    80% confidence

  • For Joby, current quarter loss per share expected to widen 5.3% YOY to -$0.20

    80% confidence

  • Management expects to generate cash, cash equivalents, and short-term investments at the upper end of $500 million to $540 million range for 2025

    80% confidence

  • For Joby, full fiscal year losses seen growing 7.6% annually to -$0.85 per share

    80% confidence

  • Joby plans to produce four aircraft a month by 2027 at Ohio facility

    80% confidence

  • For Archer current quarter, losses expected to decrease 52.8% YOY to -$0.25 per share

    80% confidence

  • Wall Street analysts recommend caution with consensus Hold rating for Joby Aviation

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of — Source | Via News | Finance Via News